


Product Information



Epalrestat

Item No. 15214

CAS Registry No.: 82159-09-9
Formal Name: 5Z-[(2E)-2-methyl-3-phenyl-2-propen-1-ylidene]-4-oxo-2-thioxo-3-thiazolidineacetic acid
Synonyms: Kinedak, ONO-2235, Sorbistat
MF: C₁₅H₁₃NO₃S₂
FW: 319.4
Purity: ≥98%
Stability: ≥2 years at -20°C
Supplied as: A crystalline solid
UV/Vis.: λ_{max}: 237, 292, 390 nm



Laboratory Procedures

For long term storage, we suggest that epalrestat be stored as supplied at -20°C. It should be stable for at least two years.

Epalrestat is supplied as a crystalline solid. A stock solution may be made by dissolving the epalrestat in the solvent of choice. Epalrestat is soluble in organic solvents such as DMSO and dimethyl formamide (DMF), which should be purged with an inert gas. The solubility of epalrestat in these solvents is approximately 2 and 10 mg/ml, respectively.

Epalrestat is sparingly soluble in aqueous buffers. For maximum solubility in aqueous buffers, epalrestat should first be dissolved in DMF and then diluted with the aqueous buffer of choice. Epalrestat has a solubility of approximately 0.5 mg/ml in a 1:1 solution of DMF:PBS (pH 7.2) using this method. We do not recommend storing the aqueous solution for more than one day.

Aldose reductase, the first enzyme of the polyol pathway, converts glucose to sorbitol in the presence of NADPH. Increased aldose reductase expression, induced by hyperglycemia, has been associated with complications of diabetes, as it can create a metabolic imbalance in tissues dependent on insulin for the uptake of glucose. Epalrestat is a carboxylic acid-based inhibitor of aldose reductase (IC₅₀ = 0.01-15 μM).¹ At 10 nM, it can suppress high glucose-induced proliferation of vascular smooth muscle cells and at 100 nM it can prevent high glucose-induced intracellular NADH/NAD⁺ increase and membrane-bound protein kinase C activation.²⁻³ Epalrestat has been shown to reduce oxidative stress in type 2 diabetic patients, significantly decreasing lipid hydroperoxide levels in erythrocytes when administered at 150 mg/day.⁴

References

1. Miyamoto, S. Molecular modeling and structure-based drug discovery studies of aldose reductase inhibitors. *Chem-Bio Informatics Journal* **2**(3), 74-85 (2002).
2. Yasunari, K., Kohno, M., Kano, H., *et al.* Aldose reductase inhibitor improves insulin-mediated glucose uptake and prevents migration of human coronary artery smooth muscle cells induced by high glucose. *Hypertension* **35**(5), 1092-1098 (2000).
3. Yasunari, K., Kohno, M., Kano, H., *et al.* Aldose reductase inhibitor prevents hyperproliferation and hypertrophy of cultured rat vascular smooth muscle cells induced by high glucose. *Arterioscler. Thromb. Vasc. Biol.* **15**(12), 2207-2212 (1995).
4. Ohmura, C., Watada, H., Azuma, K., *et al.* Aldose reductase inhibitor, epalrestat, reduces lipid hydroperoxides in type 2 diabetes. *Endocr. J.* **56**(1), 149-156 (2009).

Related Products

For a list of related products please visit: www.caymanchem.com/catalog/15214

Cayman Chemical

Mailing address

1180 E. Ellsworth Road
Ann Arbor, MI
48108 USA

Phone

(800) 364-9897
(734) 971-3335

Fax

(734) 971-3640

E-Mail

custserv@caymanchem.com

Web

www.caymanchem.com

WARNING: THIS PRODUCT IS FOR LABORATORY RESEARCH ONLY: NOT FOR ADMINISTRATION TO HUMANS. NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

SAFETY DATA

This material should be considered hazardous until information to the contrary becomes available. Do not ingest, swallow, or inhale. Do not get in eyes, on skin, or on clothing. Wash thoroughly after handling. This information contains some, but not all, of the information required for the safe and proper use of this material. Before use, the user must review the complete Safety Data Sheet, which has been sent via email to your institution.

WARRANTY AND LIMITATION OF REMEDY

Cayman Chemical Company makes **no warranty or guarantee** of any kind, whether written or oral, expressed or implied, including without limitation, any warranty of fitness for a particular purpose, suitability and merchantability, which extends beyond the description of the chemicals hereof. Cayman warrants only to the original customer that the material will meet our specifications at the time of delivery.

Cayman will carry out its delivery obligations with due care and skill. Thus, in no event will Cayman have any obligation or liability, whether in tort (including negligence) or in contract, for any direct, indirect, incidental or consequential damages, even if Cayman is informed about their possible existence.

This limitation of liability does not apply in the case of intentional acts or negligence of Cayman, its directors or its employees.

Buyer's exclusive remedy and Cayman's sole liability hereunder shall be limited to a refund of the purchase price, or at Cayman's option, the replacement, at no cost to Buyer, of all material that does not meet our specifications.

Said refund or replacement is conditioned on Buyer giving written notice to Cayman within thirty (30) days after arrival of the material at its destination. Failure of Buyer to give said notice within thirty (30) days shall constitute a waiver by Buyer of all claims hereunder with respect to said material.

For further details, please refer to our Warranty and Limitation of Remedy located on our website and in our catalog.

Copyright Cayman Chemical Company, 12/05/2013